News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
257,809 Results
Type
Article (13783)
Company Profile (281)
Press Release (243745)
Section
Business (79255)
Career Advice (147)
Deals (13172)
Drug Delivery (31)
Drug Development (50236)
Employer Resources (31)
FDA (5660)
Job Trends (5105)
News (143880)
Policy (10012)
Tag
Academia (901)
Alliances (21428)
Alzheimer's disease (701)
Approvals (5626)
Artificial intelligence (48)
Bankruptcy (97)
Best Places to Work (4402)
Biotechnology (230)
Breast cancer (43)
Cancer (450)
Career advice (128)
CAR-T (37)
Cell therapy (126)
Clinical research (39364)
Collaboration (155)
Compensation (72)
COVID-19 (995)
C-suite (36)
Cystic fibrosis (61)
Data (429)
Diabetes (51)
Diagnostics (1179)
Earnings (28406)
Events (46157)
Executive appointments (137)
FDA (5847)
Featured Employer (37)
Funding (159)
Gene therapy (104)
GLP-1 (275)
Government (1059)
Healthcare (6519)
Infectious disease (1016)
Inflammatory bowel disease (85)
IPO (7157)
Job creations (857)
Job search strategy (124)
Layoffs (179)
Legal (1371)
Lung cancer (88)
Manufacturing (52)
Medical device (2526)
Medtech (2527)
Mergers & acquisitions (6065)
Metabolic disorders (172)
Neuroscience (858)
NextGen Class of 2024 (1979)
Non-profit (839)
Northern California (671)
Obesity (98)
Opinion (87)
Parkinson's disease (53)
Patents (39)
People (24826)
Pharmaceutical (46)
Phase I (13818)
Phase II (18296)
Phase III (11634)
Pipeline (108)
Postmarket research (845)
Preclinical (5819)
Radiopharmaceuticals (201)
Rare diseases (123)
Real estate (1406)
Regulatory (8101)
Research institute (930)
Southern California (638)
Startups (1963)
United States (5744)
Vaccines (146)
Weight loss (64)
Date
Today (106)
Last 7 days (352)
Last 30 days (1582)
Last 365 days (21062)
2024 (16536)
2023 (22412)
2022 (26823)
2021 (27806)
2020 (23357)
2019 (16224)
2018 (11738)
2017 (13746)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (145)
Arizona (40)
Asia (16714)
Australia (2808)
California (1545)
Canada (576)
China (116)
Colorado (53)
Connecticut (56)
Europe (35908)
Florida (163)
Georgia (40)
Illinois (93)
Indiana (49)
Kansas (54)
Maryland (233)
Massachusetts (1252)
Michigan (42)
Minnesota (77)
New Jersey (402)
New York (474)
North Carolina (358)
Northern California (671)
Ohio (67)
Pennsylvania (337)
South America (207)
Southern California (638)
Texas (148)
Washington State (175)
257,809 Results for "atsena therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Atsena Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines Conference
September 24, 2024
·
1 min read
Press Releases
Atsena Therapeutics to Present ATSN-201 Safety and Efficacy Data at the American Academy of Ophthalmology 2024 Annual Meeting
October 10, 2024
·
3 min read
Press Releases
Atsena Therapeutics Appoints Joseph S. Zakrzewski as Board Chair
July 16, 2024
·
2 min read
Press Releases
Atsena Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ATSN-201 Gene Therapy to Treat X-linked Retinoschisis
September 18, 2024
·
4 min read
Drug Development
Atsena Therapeutics Announces Positive Clinical Data from the First Cohort of Phase I/II Trial Evaluating ATSN-201 Gene Therapy for the Treatment of X-linked Retinoschisis (XLRS)
Atsena Therapeutics today announced positive preliminary data from the first cohort of the ongoing LIGHTHOUSE study, a Phase I/II clinical trial evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis (XLRS).
May 1, 2024
·
5 min read
News
Atsena Therapeutics Announces 12-Month Safety and Efficacy Data from Phase I/II Clinical Trial of ATSN-101 in LCA1 Published in The Lancet
September 5, 2024
·
5 min read
Drug Development
Atsena Therapeutics Announces Initiation of Dosing in Second Cohort of Phase I/II Clinical Trial Evaluating ATSN-201 Gene Therapy for the Treatment of X-linked Retinoschisis (XLRS)
Atsena Therapeutics announced dosing has been initiated in the second cohort of the LIGHTHOUSE study, a Phase I/II clinical trial evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis.
March 13, 2024
·
3 min read
Press Releases
Atsena Therapeutics Receives Rare Pediatric Disease Designation from the U.S. FDA for ATSN-201 Gene Therapy to Treat X-linked Retinoschisis
August 14, 2024
·
4 min read
FDA
Atsena Therapeutics Receives Rare Pediatric Disease Designation from FDA for ATSN-101 Gene Therapy for GUCY2D-associated Leber Congenital Amaurosis (LCA1)
Atsena Therapeutics today announced the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation to ATSN-101, the company’s investigational gene therapy being evaluated in an ongoing Phase I/II clinical trial in patients with Leber congenital amaurosis.
January 16, 2024
·
3 min read
FDA
Atsena Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ATSN-101 Gene Therapy for GUCY2D-associated Leber Congenital Amaurosis (LCA1)
Atsena Therapeutics today announced the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to ATSN-101, the company’s lead investigational gene therapy for patients with Leber congenital amaurosis caused by biallelic mutations in GUCY2D (LCA1).
November 14, 2023
·
3 min read
1 of 25,781
Next
